论文部分内容阅读
[目的]观察布地奈德雾化吸入治疗对尘肺病合并感染患者的临床效果。[方法]选取2015年1月—2016年1月期间入院治疗的尘肺病合并感染患者60例,将其随机分为对照组(n=30)和观察组(n=30)。对照组患者采用常规治疗,如吸氧、解痉、平喘及对症治疗。观察组患者除上述常规治疗外,加用布地奈德雾化吸入,每日两次,每次2 mg,连续用10 d,并对两组患者治疗后的临床效果进行比较。[结果]治疗后第10天,观察组患者疗效优于对照组,差异有统计学意义(P<0.05);观察组总有效率为96.7%,高于对照组的73.3%。两组患者治疗后的肺功能较治疗前均有所改善,且观察组FEV_1、FEV_1/FVC均高于对照组,差异有统计学意义(P<0.05)。[结论]布地奈德雾化吸入治疗尘肺病合并感染的临床效果较好,值得在临床上进一步推广和应用。
[Objective] To observe the clinical effect of inhaled budesonide inhalation on patients with pneumoconiosis infection. [Methods] Sixty patients with pneumoconiosis who were admitted to hospital between January 2015 and January 2016 were randomly divided into control group (n = 30) and observation group (n = 30). The control group patients with conventional treatment, such as oxygen, spasm, asthma and symptomatic treatment. In addition to the above routine treatment, the patients in the observation group were treated with inhaled budesonide twice a day for 2 days for 10 consecutive days. The clinical effects of the two groups were compared. [Result] On the 10th day after treatment, the curative effect in the observation group was better than that in the control group (P <0.05). The total effective rate in the observation group was 96.7%, which was higher than that in the control group (73.3%). The lung function of the two groups after treatment was better than before treatment, and the observation group FEV_1, FEV_1 / FVC were higher than the control group, the difference was statistically significant (P <0.05). [Conclusion] The clinical effect of budesonide nebulized inhalation in treating pneumoconiosis complicated infection is better, and it is worth to be further popularized and applied in clinic.